Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer

2Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Bevacizumab is currently approved in association with first- and second-line 5-fluorouracil-based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness of bevacizumab in third-line settings are available. We describe a patient refractory to FOLFIRI and FOLFOX chemotherapy regimens who showed a dramatic and durable response to bevacizumab and FOLFIRI. We also review and discuss the available literature. Copyright © 2009 Multimed Inc.

Cite

CITATION STYLE

APA

Gaulin, J., Kotb, R., Turcotte, E., Berard, G., Sawan, B., Schmutz, G., & Beauregard, P. (2009). Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer. Current Oncology, 16(5), 84–86. https://doi.org/10.3747/co.v16i5.395

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free